Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
More News related to GSK
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Antigenics (AGEN) Indicated that Glaxo's malaria Vaccine Phase III Enrolled 5000 Children to Date
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
More News related to PFWD
- Phase Forward Named Private Sector Company of the Year by Mass Technology Leadership Council
- Phase Forward Signs Multi-Year Agreement with Quotient Clinical for Use of InForm(TM) Electronic Data Capture Solution
- Phase Forward (PFWD) Announces $40M Share Buyback
- Phase Forward Announces Share Repurchase Program
- Phase Forward to Present at the 18th Annual Credit Suisse Healthcare Conference
Phase Forward (NASDAQ: PFWD) today announced that GlaxoSmithKline (NYSE: GSK) has signed multi-year, multi-million dollar contracts covering Licensing and Study Support Services. GSK and Phase Forward also have a multi-year agreement in place for hosting services. Under the terms of the newly signed agreements, GSK will continue to utilize Phase Forward's InForm(TM) Integrated Trial Management solution. Since 2004, GSK has initiated nearly 600 clinical trials with Phase Forward's InForm electronic data capture solution and utilizing Phase Forward's hosting and study support services.
Related Categories
Corporate NewsStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
